MorphoSys AG
NASDAQ:MOR

Watchlist Manager
MorphoSys AG Logo
MorphoSys AG
NASDAQ:MOR
Watchlist
Price: 18.96 USD 2.43% Market Closed
Market Cap: 2.9B USD

EV/EBITDA
Enterprise Value to EBITDA

-5
Current
-5
Median
5.9
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-5
=
Enterprise Value
2.2B EUR
/
EBITDA
-431.5m EUR
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
DE
MorphoSys AG
NASDAQ:MOR
Average EV/EBITDA: 39.4
Negative Multiple: -5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 453.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.1
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
17.8
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.1
7%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.7
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
11%
1.5
AU
CSL Ltd
ASX:CSL
12.4
8%
1.5
NL
argenx SE
XBRU:ARGX
54.8
810%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
162.3
N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-13.6
2-Years Forward
EV/EBITDA
-25.4
3-Years Forward
EV/EBITDA
1 010.9